Related Experiment Videos
Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation
Y Miyoshi1, H Uemura, K Kitami
1Department of Urology, Yokohama City University School of Medicine, Kanagawa, Japan. miyoyasu@med.yokohama-cu.ac.jp
BJU International
|February 20, 2002
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2023
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2019
CT urography and urinary cytology in surveillance of endoscopically managed UTUC.
BJU international·2026
Diagnostic and therapeutic impact of genomic testing in neuroendocrine neoplasms.
Endocrine-related cancer·2026
Study on the Regulatory Mechanism of GLP-1 Receptor Agonist Liraglutide in Diabetic Corneal Epithelial Wound Healing.
Investigative ophthalmology & visual science·2026
Nanozyme-Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy.
Advanced materials (Deerfield Beach, Fla.)·2026
Cytotoxic Activity of Parotid Gland Toxins from Ingerophrynus philippinicus (Philippine Toad) Against Human Colorectal Carcinoma (HCT-116).
Asian Pacific journal of cancer prevention : APJCP·2026
Benefits of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide-1 receptor agonists in older patients with type 2 diabetes.
Diabetes & vascular disease research·2026